Table 1.

Monitoring frequency for MBD-related biochemical indicators at various stages of CKD

CKD stage	Serum phosphorus	Serum calcium	ALP	iPTH	25(OH)D
G1 – G2	6–12 months	6–12 months	6–12 months	Determine based on the baseline level and CKD progression
G3a/G3b	6–12 months	6–12 months	6–12 months	Determine based on the baseline level and CKD progression	Determine based on the baseline level and treatment interventions
G4	3–6 months	3–6 months	6–12 months, which can be shortened if iPTH is elevated	6–12 months	Determine based on the baseline level and treatment interventions
G5	1–3 months	1–3 months	6–12 months, which can be shortened if iPTH is elevated	3–6 months	Determine based on the baseline level and treatment interventions

MBD, mineral and bone disorder; CKD, chronic kidney disease; ALP, alkaline phosphatase; iPTH, intact parathyroid hormone. CKD G5 includes CKD G5D; CKD G1 – G5T refers to CKD G1 – G5.